Imunon Inc (FRA:CBO) Stock News, Headlines & Updates
Imunon Inc Stock News from GuruFocus
- 1
- 2
Jul 15, 2025
IMUNON (IMNN) Gains Nasdaq Listing Approval but Faces Price Challenge
GuruFocus News • 9:55am
IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan
Marketwired • 8:00am
IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan | IMNN Stock News
GuruFocus News • 7:17am
Jun 30, 2025
IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq's Listing Requirement, Anticipates Additional Compliance Period
Marketwired • 7:00am
Jun 18, 2025
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025
Marketwired • 8:00am
IMNN Presents Promising Phase 2 OVATION 2 Study Results at ESMO Congress | IMNN Stock News
GuruFocus News • 7:30am
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 | IMNN Stock News
GuruFocus News • 7:16am
Jun 17, 2025
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™
Marketwired • 8:00am
IMNN Showcases Positive Phase 1 Results for DNA Plasmid Vaccine | IMNN Stock News
GuruFocus News • 7:46am
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™ | IMNN Stock News
GuruFocus News • 7:17am
Jun 05, 2025
IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th
Marketwired • 7:00am
Jun 03, 2025
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study
Marketwired • 8:00am
IMNN: Promising Phase 2 Results in Ovarian Cancer Treatment | IMNN Stock News
GuruFocus News • 7:30am
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study | IMNN Stock News
GuruFocus News • 7:16am
Jun 02, 2025
IMNN Advances Cancer Treatment with Promising Phase 2 Results | IMNN Stock News
GuruFocus News • 8:01am
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
Marketwired • 8:00am
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS | IMNN Stock News
GuruFocus News • 7:16am
May 30, 2025
Imunon (IMNN) Announces Plans to Offer 22.03 Million Shares | IMNN Stock News
GuruFocus News • 4:45pm
May 28, 2025
IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire • 5:00pm
IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Marketwired • 5:00pm
IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules | IMNN Stock News
GuruFocus News • 4:30pm
May 27, 2025
Imunon (IMNN) Gains Attention with Upcoming ESMO Presentation | IMNN Stock News
GuruFocus News • 11:16am
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025
Marketwired • 8:00am
IMNN's Immune Biomarker Data to be Highlighted at ESMO 2025 | IMNN Stock News
GuruFocus News • 7:46am
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 | IMNN Stock News
GuruFocus News • 7:16am
May 26, 2025
Imunon (IMNN) Reveals Private Placement Plans with Potential for 21.6 Million Shares | IMNN Stock News
GuruFocus News • 8:15am
IMUNON (IMNN) Plans $3.25M Capital Raise Through Share Offering
GuruFocus News • 12:55am
May 24, 2025
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire • 11:00pm
May 23, 2025
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules | IMNN Stock News
GuruFocus News • 6:15pm
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Marketwired • 6:00pm
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer
Marketwired • 8:00am
IMNN Announces Promising Phase 2 Results for Ovarian Cancer Therapy | IMNN Stock News
GuruFocus News • 7:30am
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer | IMNN Stock
GuruFocus News • 7:15am
May 22, 2025
IMUNON Announces Withdrawal of Form S-1 Registration Statement
GlobeNewswire • 5:00pm
IMUNON Announces Withdrawal of Form S-1 Registration Statement
Marketwired • 5:00pm
IMUNON Announces Withdrawal of Form S-1 Registration Statement | IMNN Stock News
GuruFocus News • 4:45pm
Imunon (IMNN) Withdraws SEC Registration for Planned Public Offering | IMNN Stock News
GuruFocus News • 4:45pm
May 19, 2025
IMNN Downgraded to Hold by D. Boral Capital Analyst Jason Kolbert | IMNN Stock News
GuruFocus News • 10:34am
Imunon (IMNN) Downgraded Amid Concerns Over Financing Dilution | IMNN Stock News
GuruFocus News • 6:32am
May 15, 2025
- 1
- 2
Show
Entries
Headlines
Total 0- 1
No recent news